Finance

Cancer vaccine maker records loss of $0.60 per share

Published in Clinical Oncology Week, November 21st, 2005

Cell Genesys, Inc., (CEGE) reported a net loss of $27.3 million, or $0.60 per share for the quarter ended September 30, 2005.

This compares with a net loss of $24.0 million, or $0.54 per share, for the same quarter in 2004. The increase in net loss in the current quarter compared to the third quarter of 2004 can be attributed to increased operating losses, resulting in part from greater expenditures on our GVAX vaccine for prostate cancer program. Cell Genesys ended the quarter with approximately $102.4 million in cash, cash equivalents and short-term investments.

In addition, Cell Genesys held approximately 6.0 million shares of its former...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2005-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry